2013 Sunshine Act forecast

In 2012, the Physician Payment Sunshine Act loomed over pharmaceutical and medical device manufacturers. We entered the year arguing its merits -- some believe the act will reduce overall healthcare costs, while others think it could hurt medical innovation. It was also a time to begin reviewing and implementing transparency strategies.

But on a whole, the best way to describe 2012 as it relates to the Sunshine Act is “hurry up and wait.” One year ago CMS said it would collect feedback on the rule before issuing its final guidance. But today we’re still wondering what it all means and how it will truly impact the industry.

Over at MedCity News, our own Becky Holloway recapped the Sunshine Act events of 2012 and offered a forecast for 2013. Check it out for a play-by-play of where we've been and where we’re headed!